Flora-Biotic™ Ultra (47. 5 Billion CFU)

Flora-Biotic™ Ultra (47. 5 Billion CFU)
  • Gluten Free
  • Non-GMO
  • Vegetarian
  • Vegetable Caps

Supports intestinal microflora balance, immune system performance and healthy inflammatory response

  • 47.5 Billion CFU per capsule
  • 10 compatible probiotic strains
  • Shelf stable
  • Dairy free and soy free
  • Delayed release capsule to support viability through the intestinal tract
  • Helps balance intestinal microflora
  • Supports digestive health and immune function
  • Promotes healthy vaginal pH

Login to Order

Product Information Sheet (PDF)

Unique Properties 

Patient One Flora-Biotic™ Ultra is a ten-strain probiotic with a minimum 47.5 billion bacteria per serving at encapsulation. Patient One’s proprietary blend contains significant concentrations of well-documented strains, including L. rhamnosus, L. casei, L. acidophilus, and L. reuteri, as part of a comprehensive formula.
Flora-Biotic Ultra supplies HardiStrainTM standardized bacteria cultures, produced with a proprietary system that promotes increased viability over an extended shelf life. Our freeze-dried probiotic cultures are shelf stable and provided in an acid-resistant, delayed release capsule to survive harsh stomach acids for effective delivery to the intestinal tract where the organisms can colonize and replicate.
Flora-Biotic Ultra supports the proliferation of beneficial microbiota and helps to inhibit the growth of pathogenic bacteria, enhancing the body's ability to resist undesirable microorganisms while aiding digestion. The bacteria have the ability to adhere to the intestinal epithelial cells and to implant in the intestines and positively modulate the mucosal immune response. Certain strains promote a healthy vaginal pH. 
As strain identity is essential to link a strain to a specific health effect, the probiotic strains in our formula are genetically identified using a sophisticated RiboPrinter® microbial characterization system.  

Key Ingredients

Lactobacillus rhamnosus (ATCC 7469) 

L. rhamnosus, one of the most widely studied probiotic strains, works to balance the GI microflora. Perhaps most notable about L. rhamnosus is its ability to tolerate and even thrive in the typically acidic conditions found in the stomach. L. rhamnosus is believed to greatly assist with immune function in healthy adults, particularly in combating pathogens involved with the urinary tract system (acidic condition). 

Lactobacillus casei (ATCC 393)

L. casei is a species of Lactobacillus found in milk, cheese and dairy. A lactic-acid producer that has been found to assist in the colonization of beneficial bacteria, it supports the growth of L. acidophilus, which can help guard against constipation and irritable bowels. L.casei is active in a broad temperature and pH range and can be found naturally in the mouth and intestine of humans. As a lactase producer, it aids in the optimal digestion of lactose, promoting optimal digestive health. 

Lactobacillus reuteri (DSM 20015)

L. reuteri is found in different body sites, including the gastrointestinal tract, urinary tract, skin and breast milk. This probiotic bacterium has been studied for its diverse beneficial effects, including antimicrobial and immunomodulatory activity. A number of probiotics are known for their abilities to enhance mucosal barrier function, and L. reuteri is a well-known example. This probiotic has also been shown to support respiratory function, provide occasional relief from digestive discomfort and promote vaginal microbiota. One study showed that only 14 days of oral L. reuteri administration could restore normal vaginal flora in postmenopausal women. A total of 4 weeks of oral capsule consumption of two Lactobacilli strains including L. reuteri increased the relative abundance of Lactobacilli. 

Lactobacillus acidophilus (ATCC 4356)  

L. acidophilusa strain of lactic acid-producing microbes, offers numerous benefits for digestive health. L. acidophilus produces vitamin K, lactase and anti-microbial substances. Multiple human trials report benefits of L. acidophilus for bacterial vaginosis. Scientists have discovered that administering L. acidophilus orally helps reduce the colonization of pathogenic bacteria, such as E. coli within the digestive tract. L. acidophilus has been shown to improve digestive functions and boost the immune system. By creating a lactase enzyme that assists in the breakdown of lactose into simple sugars, L. acidophilus may be beneficial for people who experience lactose intolerance.

Bifidobacterium bifidum (BC-06)

B. bifidum is the most common probiotic bacteria in the body. It is an important constituent of the colonic microbiome and is particularly prevalent in the colon of breast-fed infants. This probiotic is often found in healthy vaginas. Bifidobacterium bifidum  directly competes with Candida and yeast overgrowths in our bodies. Candida infections are commonly associated with low concentrations of B. bifidum. Research has shown that B. bifidum produces natural antibiotic substances that kill bad bacteria. B. bifidum is also extremely susceptible to being killed by pharmaceutical antibiotics.

Bifidobacterium longum (BI-05)

B. longum is among the first to colonize the sterile digestive tract of newborn infants. There is evidence that B. longum competes for attachment sites on the intestinal mucosal membrane, preventing the colonization of pathogenic coliform bacteria. It has a high resistance to gastric acid and shares similar functions as B. bifidum, such as boosting the immune system and providing barrier protection from pathogens.

Lactobacillus brevis (Lbr-35) 

L. brevis is especially abundant in the intestines, vagina and feces. Several studies indicate that it has the ability to inhibit Helicobacter pylori, as well as to potentially reduce side effects from traditional methods of addressing H. pylori. Research shows that L. brevis can help to boost immune system function by increasing the production of natural killer cells. High amounts of this probiotic are associated with the health of the vagina. It also appears that newborns receive L. brevis from the mother through breast feeding or through natural child birth. This helps to protect the baby’s gut from pathogens and also assists with digestion. The anti-microbial properties of L. brevis are also beneficial for the health of the gums. 

Lactobacillus salivarius (ATCC 11741) 

L. salvarius, which resides in the mouth and small intestine, has been shown effective in fighting off at least five harmful bacteria that are involved in producing plaque, thus assisting in dental health. L. salivarius has a unique ability to fight off the H. pylori bacteria that are responsible for most peptic ulcers. Researchers studied animal response after induced colitis and septic shock and treatment with L. salivarius and discovered the role of L. salivarius in striving to reestablish homeostasis within the intestines. They concluded that this probiotic may be related to the immune response.

Lactobacillus bulgaricus (Lb-87) 

L. bulgaricus effectively metabolizes sugars (including starches and fibers) to produce lactic acid. The generation of lactic acid in the intestine decreases the pH of the intestinal tract which makes it less suitable for the growth of acid-tolerant microbes including those that can act as pathogens. L. bulgaricus is also effective at reducing the lactose load in individuals who are lactose intolerant, thereby allowing them to ingest higher quantities of dairy products.

Lactobacillus plantarum (NCIMB 12422) 

L. plantarum has been used in the process of fermenting foods for hundreds of years. It promotes a normal digestive tract and is able to destroy pathogens while preserving vital nutrients, antioxidants and vitamins. One of the most remarkable attributes of L. plantarum is its ability to synthesize L-lysine, an essential amino acid. L. plantarum is able to ward off harmful bacteria in the intestine by preventing the pathogenic bacteria from attaching to the mucosal lining and also by competing for nutrients that the pathogenic bacteria live on. By doing so, harmful bacteria pass harmlessly through the body.


  • In 2005 Sherman et al demonstrated that probiotics prevent epithelial injury induced by attaching-effacing bacteria. One of the most important criteria to balance effectively the intestinal flora is the ability of a probiotic to inhibit the growth of pathogens. In vitro tests have shown that L. rhamnosus is able to inhibit the adhesion to intestinal epithelial cells of both enteropathogenic E. coli O127:H6 and enterohaemorrhagic E. coli O157:H7 that cause protracted diarrhea in infants and hemorrhagic colitis, respectively.
  • L. rhamnosus down regulates the production of cytokines and chemokines associated with cell mediated immunity (TGF-?, TNF-a), and also IL-8, when it is produced by intestinal and gastric epithelial cells stimulated, by pathogen presence or inflammation. In addition, it prevents over expression of RANTES, which is apparent in inflammatory states.
  • Several clinical trials have demonstrated the efficacy of L. rhamnosus association with L. acidiphilus in reducing or preventing diarrhea of various origins. Tláskal et al (1995) evaluated two groups of children suffering from pathologies of the gastrointestinal tract. The first group (33 children) received the association of L. acidophilus and L. rhamnosus. The second group (42 children) received a conventional treatment (smectite and concentrated metabolic products of common symbiotic bacteria of the intestine). A comparison of the results of the two groups revealed a better efficacy of Lactobacilli acidophilus and rhamnosus treatment than the conventional treatment. The duration of diarrhea was reduced among the children who received the probiotics compared to the group who received the conventional treatment.
  • A study was conducted to determine if L. casei had any effect on the symptoms of Crohn's disease, and researchers concluded that L. casei can counteract the pro-inflammatory effects of E. coli on Crohn's disease.
  • Research has shown that L. rhamnosus can prevent apoptosis in gastric epithelial cells, improving the integrity of the stomach lining. A review article in the American Journal of Clinical Nutrition reported that L. rhamnosus can reduce the duration of diarrhea caused by rotavirus and other causes.


  1. Altieri C., Bevilacqua A., Sinigaglia M. Prolonging the Viability of Lactobacilus plantarum through the Addition of Prebiotics into the Medium. Journal of Food Science, 2011; 76, Nr.6, M336-M345.
  2. Mu Q., Tavella V., Luo X., Role of Lactobacillus reuteri in Human Health and Diseases. Frontiers in Microbiology, 2018; 9:757
  3. Seockmo Ku, Myeong Soo Park, Geun Eog Ji, and Hyun Ju You. Review on Bifidobacterium bifidum BGN4: Functionality and Nutraceutical Applications as a Probiotic Microorganism. International Journal of Molecular Sciences, 2016.
  4. Sherman PM., Johnson-Kenry KC. Yeung HP. Ngo SC., Goulet J., Tompkins TA. Probiotics reduce enterohemorrhagic Escherichia coli )157:H7- and enteropathogenic E. coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect. Immun., 2005; 73: 5183—8.
  5. Tiáskal P, Lactobacillus acidophilus in the treatment of children with gastrointestinal tract illness. 1995, Cesko-Slovenska Pediatrie, 51 :615-619.
  6. Waldemar G., Kordowska-Wiater M., Koziol J. The influence of selected prebiotics on the growth of lactic acid bacteria for bio-yoghurt production. Acta Sci. Pol. Technol. Aliment. 2011; 10(4) 455-466.
  7. Wallace TD. Bradley S., Buckley ND. Green-Johnson JM. Interactions of lactic acid bacteria with human intestinal epithelial cells: Effects on Cytokine production. Journal of Food Protection, 2003; 66, 3; 446-472.
  8. Wood C., Keeling S., Bradley S., Johnson-Green P., Green-Johnson JM. Interactions in the mucosal microenvironment: Vasoactive intestinal peptide modulates the down regulatory action of Lactobacillus rhamnosus on LPS indusced interlukin-8 production by intestinal epithelial cells. Microbial Ecology in Health and Disease, 2007; 1-10.

Supplement Facts

Serving Size: 1
Servings Per Container: 60
Amount Per Serving % Daily Value**
Bacterial Culture Blend (minimum 47.5 Billion CFU)* 475 mg
L. rhamnosus (ATCC 7469)
L. casei (ATCC 393)
L. reuteri (DSM 20015)
L. acidophilus (ATCC 4356)
B. bifidum (BC-06)
B. longum (BI-05)
L. Brevis (Lbr-35)
L. salivarius (ATCC 11741)
L. bulgaricus (Lb-87)
L. plantarum (NCIMB 12422)
† Daily Value not established.

Suggested Use

Take 1 capsule daily as a dietary supplement, with or between meals, or as directed by your health practitioner. Store in a cool, dry place. Shelf stable at room temperature. Refrigeration may prolong long-term stability. Keep desiccant in bottle.


If you are pregnant, nursing, or taking any medications, consult your health practitioner before use. Discontinue use and consult your health practitioner if any adverse reactions occur. Keep out of reach of children. Use only if safety seal is intact.

Flora-Biotic™ Ultra (47. 5 Billion CFU) Label